or Try an Advanced Search...

    Non Small Cell Lung Cancer Stocks List

    Symbol Grade Name % Change
    LCTX D Lineage Cell Therapeutics, Inc. -6.52
    TIL D Instil Bio, Inc. 4.99
    GNLX D Genelux Corporation -2.41
    ACHV F Achieve Life Sciences, Inc. 0.81
    NXTC F NextCure, Inc. -1.48
    CGEM F Cullinan Management, Inc. -3.46
    BCAB F BioAtla, Inc. -6.70
    CCCC F C4 Therapeutics, Inc. -3.21
    ADAP F Adaptimmune Therapeutics plc -3.63
    LYEL F Lyell Immunopharma, Inc. -8.60
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Instruments & Supplies
    Related Stock Lists: Cancer Small Cell Lung Cancer Medicine Clinical Medicine Solid Tumors Biopharmaceutical Biotechnology Prostate Cancer Advanced Cancer Antibodies Breast Cancer Cancer Treatment Clinical Trial Immunology Immunotherapies Immunotherapy Infectious Diseases Metabolic Disorders Monoclonal Antibodies Multiple Myeloma

    Related ETFs - A few ETFs which own one or more of the above listed Non Small Cell Lung Cancer stocks.

    Symbol Grade Name Weight
    PBE D PowerShares Dynamic Biotech & Genome 2.78
    OZEM F Roundhill GLP-1 & Weight Loss ETF 1.72
    XHE B SPDR S&P Health Care Equipment 1.65
    CNCR F Loncar Cancer Immunotherapy ETF 1.54
    HTEC C Robo Global Healthcare Technology and Innovation ETF 1.5
    View all Non Small Cell Lung Cancer ETFs...
    Compare ETFs
    Compare OZEM to HTEC Compare PBE to CNCR Compare PBE to XHE

        Non Small Cell Lung Cancer Stocks Recent News

        Date Stock Title
        Nov 20 CCCC C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
        Nov 19 NXTC Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
        Nov 16 ADAP Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
        Nov 15 TIL Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
        Nov 15 GNLX Genelux GAAP EPS of -$0.19 beats by $0.01
        Nov 15 GNLX These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
        Nov 15 ADAP Halozyme bids for Evotec; BeiGene gets a new name
        Nov 14 GNLX Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Long-Term Care Facilities Medical Instruments & Supplies
        Related Stock Lists: Cancer Small Cell Lung Cancer Medicine Solid Tumors Antineoplastic Drugs Biotechnology Clinical Medicine Immunology Treatment Of Non Small Cell Lung Cancer Acute Myeloid Leukemia Antibodies Antibody Biopharmaceutical Cancer Treatment Chemotherapy Clinical Trial Epidermal Growth Factor Receptor Human Monoclonal Antibodies Immune System Immunotherapy
        Non Small Cell Lung Cancer

        Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases. It is a type of cancer that begins in the cells that line the airways of the lungs. NSCLC is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Symptoms of NSCLC include a persistent cough, chest pain, shortness of breath, and coughing up blood. Treatment options for NSCLC include surgery, chemotherapy, radiation therapy, and targeted therapy.

        Browse All Tags